Leukemia (2013) 27, 1419-1422; doi:10.1038/leu.2012.318
Although the majority of patients with Hodgkin Lymphoma (HL) are cured by first-line therapy, there remains a group of 25-30% who either fail to achieve complete response (CR) with initial chemotherapy or who subsequently relapse. Increasing the intensity of primary treatment reduces this failure rate, but this must be balanced against greater toxicity and the debate surrounding the most appropriate first-line therapy continues. 1 Autologous stem cell transplantation (ASCT) was established as the treatment of choice for relapsed HL in two randomised trials, resulting in long-term disease-free survival in 40-50% of those who achieved at least a partial response (PR) with first-line salvage. 2, 3 However, for those patients who fail to achieve PR, those who relapse o12 months from the completion of initial treatment, those with extranodal disease at relapse, and those with primary resistant disease (less than CR, or progression within 3 months of completion of therapy) the prognosis is considerably worse. 4, 5 More recently, the prognostic value of functional imaging in predicting outcomes of patients with recurrent or refractory HL has been evaluated. 6, 7 Those with negative studies (metabolic CR, mCR) before ASCT had favourable outcomes (3-5 year progression-free survival (PFS) 470%). Those with chemosensitive disease but with residual metabolic activity, which occurred in 55-60% of those with PR by computerised tomography (CT) following first-line salvage, had only a 25-30% 3-5 year PFS. To improve the outcome after failure of primary therapy, alternative strategies are required for patients who fail to normalise functional imaging pre-ASCT.
Allogeneic hematopoietic stem cell transplantation is one possibility in these high-risk patients, although its use was previously limited by high procedure-related mortality. Reducedintensity strategies have improved non-relapse-related mortality (NRM) rates, 8, 9 allowing re-evaluation of a potential role in these patients. 10, 11 We evaluated a fluorodeoxyglucose-positron emission tomography (FDG-PET)-directed transplant strategy using a more intensive conditioning protocol and report a retrospective analysis of mature data (median follow-up of 3.3 years) from this uniformly treated cohort. PET-CT scans were assessed in keeping with consensus recommendations incorporating visual analysis using a 5-point scale being applied in concurrent prospective lymphoma studies in the UK and subsequently ratified in the Deauville criteria, with a threshold of 4 or above considered positive. 12, 13 Patients attaining mCR to firstline salvage received conventional consolidation with an autograft (carmustine (BCNU) 300 mg/m 2 on day À 6, etoposide 200 mg/m 2 once daily and cytarabine 200 mg/m 2 twice daily on days À 5 to À 2, and melphalan 140 mg/m 2 on day À 1 (BEAM)). Patients were considered for allogeneic transplantation if they failed to attain mCR to initial salvage, had at least stable disease following most recent salvage, and had an appropriate donor (fully HLA-matched sibling or 8-10/10 HLA-matched unrelated).
Sixty-one consecutive patients with biopsy-proven HL and either primary resistant or relapsed disease received salvage therapy at our institution between November 2007 and December 2010. All gave written informed consent for treatments received, and for collection of the data presented. Three of the responses to donor lymphocytes were reported previously. 11 Patient characteristics are listed in Table 1 . The majority (55/61, 90.2%) received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) as first-line therapy, and ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) as first-line salvage (53/61, 86.9%). Twentyeight (45.9%) proceeded to ASCT of whom two had failed to achieve mCR following the first-line therapy (both scoring 4 on the visual analysis scale). In one, there was difficulty identifying a donor, the patient achieved mCR following a further line of therapy and proceeded to autograft. In the other, relapse occurred 2.5 years following primary therapy with only a single site of nodal disease following first-line salvage, and mCR following a single cycle of an alternative line of therapy. Only two patients scored 3 on the visual analysis scale following first-line salvage and both proceeded to ASCT. The autograft cohort included the majority of patients with 'late' relapse (412 months), but also a significant number with 'early' relapse or primary resistant disease ( Table 1) . As expected, the rigorous selection of patients proceeding to ASCT resulted in excellent results in this group. Non-relapserelated mortality occurred in only one patient (3.6% (95% confidence interval: 0.5-24.5%)) ( Figure 1a ). Relapse occurred in three patients at 9-12 months post-transplant (10.7% (3.7-31.2%)) ( Figure 1b ). This included both patients scoring 3 on the visual analysis scale following first-line salvage, and one of those who had received a second-line salvage to achieve mCR. Three-year overall and PFS following ASCT was 92.9% (83.3-100%) and 85.7% (72.8-98.7%), respectively ( Figure 1c ).
Of the remaining 33 patients, eight (13.1% of the entire cohort) either failed to achieve sufficient response to proceed to highdose therapy (n ¼ 3), or developed complications associated with salvage that precluded such consolidation (n ¼ 5) (Table 1) . Seven with primary resistant disease died of disease progression, whereas one with 'late' relapse and significant cardiac impairment following salvage therapy remains in CR 18 months following discontinuation of salvage.
Twenty-five patients proceeded to allograft. All but one received a cisplatin-containing regimen as first-line salvage and all had persistent FDG-avid lesions (visual analysis scores 4-5) following this. Nine had progressive disease, four had stable disease and 12 achieved a PR, although seven of this latter group required further lines of salvage because of progression before planned allograft, and one required further cytoreduction of bulky disease. Conditioning consisted of BEAM-alemtuzumab in twentyfour cases and fluadarabine-melphalan-alemtuzumab 8 in one, who had required eight lines of salvage. Patients with fully HLAmatched (10/10) donors received alemtuzumab 10 mg per day and those with HLA-mismatched donors received 20 mg per day on days À 5 to À 1.
Following allogeneic HSCT, patients were restaged using PET-CT every 3 months for the first year, then at 18, 24 and 36 months. The development of new FDG-avid lesions scoring 4-5 on the visual analysis scale in the absence of other potential causative pathologies, or 'significant' increase in SUV of over 25% in previously positive lesions was considered compatible with relapse/progression. Biopsies were performed where feasible, and repeat PET-CT studies at 6-8 weeks in equivocal cases, where biopsy was not possible. Lineage-specific chimerism was assessed by PCR analysis of short tandem-repeat loci every 3 months. In the All patients engrafted, with a median time to both neutrophil and platelet engraftment of 11 days. Four developed grade II and one grade III GvHD, and only one developed extensive chronic GvHD (all with unrelated donors). Two patients (8.0% (2.1-30.2%)) died of NRM, related to sepsis and GvHD in one, and idiopathic pneumonitis in the other (Figure 1d ). Twenty-three were evaluable for chimerism status from 3 months post-transplant. Fifteen were mixed chimeras in the T-cell lineage (5-95% recipient). All converted to full donor status (o5% recipient) following cyclosporine withdrawal or donor-lymphocytes (Supplementary Figure 1) .
Relapse or progression occurred in six patients (biopsied in four), with a 3-year cumulative incidence of 24.0% (12.0-48.2%) (Figure 1e ). Five had primary resistant disease and one had experienced early relapse following primary therapy. Five had residual disease before transplant and one was in mCR. One had Grade II GvHD and refused further treatment. One achieved a partial metabolic response following donor-lymphocytes, but with further progression within 6 months. One achieved mCR following brentuximab vedotin consolidated by donor-lymphocytes and remains in mCR at latest follow-up. The other three patients achieved mCR following 2-5 doses of donor-lymphocytes without additional cytoreductive therapy. In addition, two patients had persistent FDG-avid lesions at 3 months post-transplantation but with a reduction in size and FDG-avidity. Both had mixed T-cell chimerism and had cyclosporine rapidly tapered. Scans remained stable at 6 months with persisting mixed chimerism in one, who began a dose-escalating donor-lymphocyte programme with subsequent resolution of FDG-avid lesions following 3 Â 10 6
CD3
þ cells per kg. The other developed GvHD following withdrawal of cyclosporine in association with conversion to full donor chimerism and resolution of FDG-avid lesions. There were no deaths attributable to donor-lymphocyte-related toxicities, and only two patients developed GvHD requiring systemic immune suppression.
Three-year overall and PFS in the allograft cohort was 88.0% (75.3-100%) and 68.0% (49.7-86.3%), respectively (Figure 1f ). Current PFS (cPFS) was 80.0% (64.3-95.7%) (Figure 1f) . Three-year overall, progression-free and cPFS for the entire cohort of 53 patients undergoing transplant procedures was 90.6% (82.7-98.4%), 77.4% (66.1-88.6%) and 83.0% (72.9-93.1%), respectively, with corresponding NRM and relapse incidences of 5.7% (1.9-17.0%) and 17.0% (9.4-30.8%) (Figures 1g-i) . In the context of the entire cohort of 61 patients, overall survival is 77.3% (66.7-88.8%) 4 years following initiation of salvage therapy (not shown). Of the 49 patients currently alive, 42 remain progression-free and six are currently in mCR after further salvage.
Moskowitz et al. 14 recently reported that attainment of mCR following second-line salvage therapy in those with exclusively nodal disease may identify a subgroup with better outcomes post ASCT, whereas those with extranodal disease continued to fair poorly even if mCR was achieved. Only three of our cohort fulfilled these criteria, predictive of favourable outcomes. Two remain progression-free post allogeneic transplantation and one Letters to the Editor following ASCT. The issue of whether this subgroup would be more appropriately treated with an ASCT will require further investigation in larger patient cohorts.
In summary, these data illustrate a number of important findings. First, they show that the majority of patients with late relapse following primary therapy achieve mCR following a single line of salvage and that the outcomes in these patients following ASCT are extremely good. Second, they show that a subgroup of patients with early relapse or primary resistant disease also achieve mCR following a single line of salvage (14/47, 29.8%) and that these patients appear to have similarly favourable outcomes following ASCT. All remain alive and disease-free, suggesting that PET-based selection for ASCT is appropriate and that the escalation of therapy is unnecessary. Third, they demonstrate that a group identified to be at high risk of treatment failure following ASCT achieve favourable outcomes following allogeneic transplantation using a conditioning regimen at the more intensive end of the spectrum. This cohort was high-risk, as determined by PET status post salvage, but also by other conventional criteria, including 24 (96%) with primary resistant or early relapsed disease, 23 (92%) with stage IIB, III or IV disease, and 14 (56%) with extranodal disease. The cPFS following allogeneic transplantation was 80.0%. This was possible not only because of the high tumour-response rate, but also because of the low rates of both acute and chronic GvHD associated with T-cell depletion. The demonstration of favourable outcomes following this response-adjusted transplantation strategy suggests that PETdirected transplantation strategies warrant further evaluation in patients with primary resistant or relapsed HL, potentially allowing further the refinement of criteria by which patients are riskstratified to appropriate consolidation modalities.
CONFLICT OF INTEREST
The authors declare no conflict of interest. identified a second patient. Sequencing of the PCR products showed that the first three exons of RCSD1 were fused to ABL1, starting at exon 4. We obtained biological samples from patients diagnosed in Finland, United Kingdom, Kuwait and Ecuador. Five patients (three males and two females) were then included in this study (Table 1) . Their age ranged from 11 to 40 years. All had B-cell ALL. Immunophenotyping showed the blasts to be CD10 þ , CD19 þ , CD22 þ , CD24 þ and CD79a þ . One patient, Pt 4, was lost to follow-up soon after diagnosis. A complete remission was achieved in three patients (Pts 1, 2 and 3) while one patient, Pt 5, was not compliant to treatment and did not achieve complete remission. Three of the four patients for whom data were available (Pts 1, 3 and 5) were still alive, survival ranging from 12 to 97 months. One patient, Pt 1, received bone marrow transplantation 31 months following diagnosis (after a first relapse) and was alive 66 months later. Another patient, Pt 3, had allogeneic hematopoietic stem cell transplantation 4 months following diagnosis but relapsed 12 months later. A third patient, Pt 2, had three bone marrow transplantations, each time following relapse, but died 84 months following diagnosis.
Conventional cytogenetics on bone marrow cells using R-and/ or G-and/or Q-banding revealed a clone containing a t(1;9)(q24;q34) along with a normal clone in four patients while additional material of unknown origin was identified at chromosome Xp22 in the t(1;9)-containing clone in the fifth patient (P1)
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